Securities and Exchange Commission
Washington, D.C. 20549
FORM 10-QSB
[ X ] QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended October 31, 2005
[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE
EXCHANGE ACT
For the transition period from ________________ to ________________
Commission file number 0-11485
ACCELR8 TECHNOLOGY CORPORATION
------------------------------
(Exact name of small business issuer as specified in its charter)
COLORADO 84-1072256
-------- ----------
(State or other jurisdiction (IRS Employer Identification No.)
of incorporation or organization)
7000 Broadway, Bldg., 3-307. Denver, CO 80221
---------------------------------------------
(Address of principal executive office)
(303) 863-8088
--------------
(Issuer's telephone number)
(Former name, former address and former fiscal year,
if changed since last report)
Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Yes [X] No [ ]
Number of shares outstanding of the issuer's Common Stock:
Class Outstanding at December 12, 2005
------------------------------------- ------------------------------------
Common Stock, no par value 9,971,210
INDEX
-----
Page
----
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Balance Sheets 3
October 31, 2005 (unaudited) and July 31, 2005
Statements of Operations 4
for the three months ended October 31, 2005
and 2004 (unaudited)
Statements of Cash Flows 5
for the three months ended October 31, 2005
and 2004 (unaudited)
Notes to Unaudited Financial Statements 6
Item 2. Management's Discussion and Analysis of 9
Financial Condition and Results of Operations
Item 3. Controls and Procedures 17
PART II. OTHER INFORMATION
Item 1. Legal Proceedings 17
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 17
Item 3. Defaults Upon Senior Securities 17
Item 4. Submission of Matters to a Vote of Security Holders 17
Item 5. Other Information 17
Item 6. Exhibits and Reports on Form 8-K 17
SIGNATURES 19
CERTIFICATION OF OFFICERS 20
2
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
----------------------------
Accelr8 Technology Corporation
Balance Sheets
ASSETS
October 31, July 31,
2005 2005
------------ ------------
(Unaudited)
Current assets:
Cash and cash equivalents $ 4,922,054 $ 5,564,259
Accounts receivable 23,370 44,347
Inventory 27,244 27,244
Prepaid expenses and other current assets 226,043 228,097
Note receivable (Note 7) 0 266,667
------------ ------------
Total current assets 5,198,711 6,130,614
Property and equipment, net 235,389 230,847
Investments, net 839,925 767,637
Intellectual property, net (Note 3) 3,819,799 3,878,969
------------ ------------
Total assets $ 10,093,824 $ 11,008,067
============ ============
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 180,035 $ 153,408
Accrued compensation and other liabilities 68,989 278,682
Deferred revenue (Note 4) 72,000 65,000
------------ ------------
Total current liabilities 321,024 497,090
Long-term liabilities:
Deferred compensation 858,948 842,637
------------ ------------
Total liabilities 1,179,972 1,339,727
------------ ------------
Commitments and Contingencies
Shareholders' equity (Notes 6)
Common stock, no par value; 12,000,000 shares
(after increase on December 14, 2004) and
11,000,000 respectively authorized; 9,971,210
and 9,961,210 shares, issued and outstanding,
respectively 12,878,020 12,863,020
Contributed capital 486,099 483,549
Accumulated deficit (4,176,667) (3,404,629)
Shares held for employee benefit (1,129,110 shares at cost) (273,600) (273,600)
------------ ------------
Total shareholders' equity 8,913,852 9,668,340
------------ ------------
Total liabilities and shareholders' equity $ 10,093,824 $ 11,008,067
============ ============
See accompanying notes to unaudited financial statements.
3
Accelr8 Technology Corporation
Statements of Operations
For the three months ended October 31, 2005 and 2004
(Unaudited)
2005 2004
----------- -----------
Revenues:
OptiChem Revenues $ 44,388 $ 21,724
Technical Consulting 15,000 0
Development Fees 27,000 0
----------- -----------
Total Revenues 86,388 21,724
----------- -----------
Costs and expenses:
Research and development 572,911 203,149
General and administrative 212,251 261,056
Amortization (Note 4) 59,171 58,698
Marketing and sales 28,479 10,749
Depreciation 19,031 15,405
Cost of sales - OptiChem(TM) 13,892 10,530
----------- -----------
Total costs and expenses 905,735 559,587
----------- -----------
Loss from operations (819,347) (537,863)
----------- -----------
Other (expense) income:
Interest and dividend income 47,372 28,766
Unrealized gain (loss) on investments (8,063) (703)
Other income 8,000 0
----------- -----------
Total other income 47,309 28,063
----------- -----------
Loss from operations $ (772,038) $ (509,800)
=========== ===========
Net loss per share:
Basic and diluted net loss per share $ (.08) $ (.05)
=========== ===========
Weighted average shares outstanding 9,971,210 9,961,210
=========== ===========
See accompanying notes to unaudited financial statements.
4
Accelr8 Technology Corporation
Statements Of Cash Flows
For the Three months Ended October 31, 2005 and 2004
(Unaudited)
2005 2004
----------- -----------
Cash flows from operating activities:
Net loss from continuing operations $ (772,038) $ (509,800)
Adjustments to reconcile net (loss) to net cash
(used in) operating activities:
Depreciation 19,031 15,405
Amortization 59,170 58,698
Increase in fair value of stock options
Granted for services 2,550 -0-
Unrealized holding (gain) loss on investments 2,713 (1,411)
(Increase) decrease in assets:
Accounts receivable 20,977 53,061
Inventory -0- 4,366
Prepaid expense and other 2,053 3,521
Increase (decrease) in liabilities:
Accounts payable 26,627 18,876
Accrued liabilities (209,693) 9,051
Deferred revenue 7,000 30,000
Deferred compensation 16,311 20,161
----------- -----------
Net cash used in operating activities (825,299) (298,072)
----------- -----------
Cash flows from investing activities:
Receipt of note payment 266,667 -0-
Issuance of Common Stock 15,000 -0-
Purchases of equipment (23,573) (3,287)
Cost of obtaining patents and trademarks -0- (5,985)
Contribution to deferred compensation trust (75,000) (75,000)
----------- -----------
Net cash used in investing activities 183,094 (84,272)
----------- -----------
Cash used by discontinued operations -0- (35,925)
----------- -----------
Decrease in cash (642,205) (418,269)
Beginning balance 5,564,259 7,233,430
----------- -----------
Ending balance $ 4,922,054 $ 6,815,161
=========== ===========
See accompanying notes to unaudited financial statements.
5
Accelr8 Technology Corporation
Notes to Financial Statements
Note 1. Basis of Presentation
The financial statements included herein have been prepared by Accelr8
Technology Corporation (the "Company") without audit, pursuant to the rules and
regulations of the United States Securities and Exchange Commission ("SEC").
Certain information and footnote disclosures normally included in the financial
statements prepared in accordance with generally accepted accounting principles
have been condensed or omitted as allowed by such rules and regulations. The
Company believes that the disclosures are adequate to make the information
presented not misleading. These financial statements should be read in
conjunction with our annual audited financial statements dated July 31, 2005,
included in our annual report on Form 10-KSB as filed with the SEC.
Management believes that the accompanying unaudited financial statements are
prepared in conformity with generally accepted accounting principles, which
require the use of management estimates, and contain all adjustments (including
normal recurring adjustments) necessary to present fairly the operations and
cash flows for the periods presented. The results of operations for the three
months ended October 31, 2005 may not be indicative of the results of operations
for the year ended July 31, 2006.
Note 2. Reclassification
Certain reclassifications have been made in the fiscal 2005 financial statements
to conform to the classifications used in fiscal 2006. Such reclassifications
have no effect on net income (loss) as previously reported.
Note 3. Intellectual Property
Intellectual property consisted of the following:
October 31, 2005 July 31, 2005
---------------- -------------
OptiChem Technologies $ 4,454,538 $ 4,454,538
Patents 223,991 223,991
Trademarks 49,019 49,019
----------- -----------
Total intellectual property 4,727,548 4,727,548
Accumulated amortization (907,749) (848,579)
----------- -----------
Net intellectual property $ 3,819,799 $ 3,878,969
=========== ===========
Intellectual properties are recorded at cost and are being amortized on a
straight-line basis over their estimated useful lives of 20 years, which
approximates the patent and patent application life of the OptiChem
technologies. Amortization expense was $59,170 and $58,698 respectively, for the
three months ended October 31, 2005 and 2004.
6
Accelr8 Technology Corporation
Notes to Financial Statements
Note 3, continued:
The Company routinely evaluates the recoverability of its long-lived assets
based upon estimated future cash flows from or estimated fair value of such
long-lived assets. If in management's judgment, the anticipated undiscounted
cash flows or estimated fair value are insufficient to recover the carrying
amount of the long-lived asset, the Company will determine the amount of the
impairment, and the value of the asset will be written down. Management believes
that the fair value of the technology exceeds the carrying value. However, it is
possible that future impairment testing may result in intangible asset
write-offs, which could adversely affect the Company's financial condition and
results of operations.
Note 4. Deferred Revenue
The deferred revenue amount of $50,000 is composed of prepaid royalty fees of
$50,000 included in the "License Agreement" with SCHOTT and $22,000 related to
the Promega agreement. See Note 5.
Note 5. License and Supply Agreements
SCHOTT Slide H Agreement
On November 24, 2004, the Company entered into a worldwide exclusive
manufacturing and marketing license agreement (the "License Agreement") with
SCHOTT Jenaer Glas GmbH ("SCHOTT"). The Company also entered into a supply
agreement (the "Slide "H" Supply Agreement") with SCHOTT for OptiChem coated
amine-reactive slides manufactured by the Company.
Pursuant to the License Agreement SCHOTT paid the Company a non-refundable fee
of $100,000, of which $50,000 was credited against future royalties. (See Note
4) An additional $15,000 has been recorded for training supplied to SCHOTT.
During the 2-year term of the License Agreement SCHOTT agreed to pay the Company
a royalty payment equal to 6% of net sales of products licensed under the
License Agreement. If the total net sales during the initial 2-year term equal
or exceed $1,125,000, then the total royalty payable by SCHOTT for the initial
term shall be a flat fee of $90,000. An optional 1-year extension may be
exercised by SCHOTT by payment of a $90,000 upfront renewal fee.
Pursuant to the Slide "H" Supply Agreement, the Company supplied SCHOTT 10,000
OptiChem coated microarraying slides, including 1,000 slides purchased prior to
the execution of the Supply Agreement, at a price of $14.00 each. The Supply
Agreement also included an option to SCHOTT until December 31, 2005 to negotiate
an exclusive license for the application of OptiChem coatings on multi-well
microtiter plates. In return, SCHOTT provided 7,500 glass substrates to the
Company at no charge. The option is valued at $12,750 and has been recorded as
option fees. The supply agreement was amended on April 25, 2005 to include the
purchase of an additional 5,000 slides through July 15, 2005 under the same
terms.
7
Accelr8 Technology Corporation
Notes to Financial Statements
Note 5, continued
SCHOTT, Slide HS Agreement
On June 2, 2005, the Company and SCHOTT entered into a second supply agreement
(the "HS Supply Agreement") for an additional formula of OptiChem (Slide HS).
Pursuant to the HS Supply Agreement, the Company will supply a minimum of 5,000
OptiChem Slide HS streptavidin coated microarrying slides to SCHOTT on a
non-exclusive basis, at a price of $20.82 each for the first 1,000 slides and
$17.15 for the remaining slides. This Supply Agreement expires on December 31,
2005. The Company also granted an option for SCHOTT to receive a non-exclusive
right to manufacture and sell, up to 12,500 glass slides, from January 1, 2006
to December 31, 2006. SCHOTT exercised this right, and will pay the Company
$15,000 for training on manufacturing of Slide HS. In addition, for this right,
SCHOTT has provided 7,500 glass substrates to the Company at no charge. The
slides are valued at $12,750 and that amount was been recorded as option fees
prior to the fiscal year end.
The Company also granted SCHOTT the right to negotiate an exclusive right for
the manufacturing and worldwide sales of Slide HS coatings on microarraying
slides. SCHOTT must formally initiate negotiations by October 1, 2005 and
complete the agreement by December 31, 2005. On September 27, 2005, SCHOTT also
provided written notification, in accordance with the HS Supply Agreement, that
it intends to exercise its exclusive right for the manufacturing an worldwide
sales of Slide HS coatings on microarraying slides. As of this filing there is
no final outcome to these negotiations.
Feasibility Testing Agreement
Effective October 5, 2005, the Company and Promega Corporation ("Promega")
entered into a Feasibility Testing Agreement (the "Agreement"). Pursuant to the
Agreement, the Company will focus on the development of a customized coating for
a glass slide for a product owned by Promega. The Agreement requires that the
feasibility testing be divided into two phases. Promega will pay the Company
$49,000 in return for Accelr8's performance under the Agreement. If Promega
determines that Phase 1 is not successfully completed, the Company will return
$22,000 to Promega and the Company will have no further obligation under the
Agreement.
Note 6. Employee Stock Based Compensation
Common Stock Options At October 31, 2005, there were 960,000 stock options
outstanding at prices ranging from $1.45 to $3.20 with expiration dates between
May 6, 2006 and March 16, 2015. For the three months ended October 31, 2005 and
2004, stock options exercisable into 960,000 and 702,500 shares of common stock,
respectively, were not included in the computation of diluted earnings per share
because their effect was antidilutive.
8
Accelr8 Technology Corporation
Notes to Financial Statements
Note 6, continued
Contingent Options
On July 12, 2003, the Company issued 50,000 options at an exercise price of
$2.25 each, to purchase all rights in technology known as YoDx which will be
integrated into the Company's existing technology. In connection with the
purchase of the YoDx technology, the Company agreed to issue an additional
200,000 stock options with the same terms upon the earlier of (a) the Company
achieving certain accumulated revenue levels associated with the YoDx(TM)
technology, as defined in the agreement, or (b) a change in control of the
Company prior to the expiration date of the options. As of October 31, 2005, the
contingent provisions have not been met and the options have not been granted.
The Company has reserved a sufficient number of shares for such options.
In December 2002, the Financial Accounting Standards Board ("FASB") issued
Statement of Financial Accounting Standards ("SFAS") No. 148, "Accounting for
Stock-Based Compensation--Transition and Disclosure--an amendment of FASB
Statement No. 123." SFAS No. 148 amends SFAS No. 123, "Accounting for
Stock-Based Compensation," to provide alternative methods of transition for a
voluntary change to the fair value based method of accounting for stock-based
employee compensation. In addition, SFAS No. 148 amends the disclosure
requirements of SFAS No. 123 to require prominent disclosures about the method
of accounting for stock-based employee compensation and the effect of the method
used on reported results in both annual and interim financial statements. The
Company accounts for employee stock-based compensation arrangements using the
intrinsic value method in accordance with Accounting Principals Board ("APB")
No. 25 and related interpretations and has adopted the disclosure-only
provisions of SFAS No. 123 as amended by SFAS No. 148.
The following table illustrates the effect on net loss if the Company had
applied the fair value recognition provisions of SFAS No. 123 to stock-based
compensation.
Three Months Ended
October 31,
2005 2004
----------- -----------
Net loss - as reported $ (772,038) $ (509,800)
Deduct: Total stock-based compensation
expense determined under fair value
based method for all awards 0 (1,025)
----------- -----------
Pro forma net loss $ (772,038) $ (510,825)
=========== ===========
Earnings per share:
Basic and diluted - as reported $ (.08) $ (.05)
=========== ===========
Basic and diluted - pro forma $ (.08) $ (.05)
=========== ===========
9
Accelr8 Technology Corporation
Notes to Financial Statements
Note 6, continued:
In December 2004, the FASB issued SFAS No. 123 (revised 2004), "Share-Based
Payment" (SFAS 123R), which replaces SFAS 123 and supersedes APB Opinion No. 25.
SFAS 123R requires all share-based payments to employees, including grants of
employee stock options, to be recognized in the financial statements based on
their fair values. The proforma disclosures previously permitted under SFAS 123
no longer will be an alternative to financial statement recognition. For the
Company, SFAS 123R is effective for periods beginning after December 15, 2005.
Early application of SFAS 123R is encouraged, but not required. We plan to adopt
SFAS 123R on February 1, 2006 using the modified prospective application method
described in the statement. Under the modified prospective application method,
we will apply the standard to new awards, and to awards modified, repurchased,
or cancelled after the required effective date. Additionally, compensation cost
for the unvested portion of awards outstanding as of the required effected date
will be recognized as compensation expense as the requisite service is rendered
after the required effective date.
Note 7. Sale of Software Migration Tools
On July 30, 2004, we completed the sale of the assets which consisted of tools
for legacy-code modernization and the resale of third-party software (the
"Software Migration Business") to Transoft Group Ltd. (the "Asset Sale"). The
aggregate purchase price of the Asset Sale was $500,000; which was payable
$100,000 in cash and the Company was issued a promissory note payable in three
equal annual installments of $133,333 with annual interest of 4% on the unpaid
balance payable quarterly. In addition, the purchase price included the
assumption of support obligations under pre-existing support and maintenance
agreements. The balance of the note payable was paid in the quarter ended
October 31, 2005.
10
Accelr8 Technology Corporation
Item 2. Management's Discussion and Analysis of Financial Condition and Result
of Operations
------------------------------------------------------------------------------
Forward Looking Information
This Quarterly Report on Form 10-QSB contains certain forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as
amended (the "Securities Act") and Section 21E of the Securities Exchange Act of
1934, as amended (the "Exchange Act"), and the Company, intends that such
forward-looking statements be subject to the safe harbors created thereby. These
forward-looking statements, which can be identified by the use of words such as
"may," "will," "expect," "anticipate," "estimate," or "continue," or variations
thereon or comparable terminology, include the plans and objectives of
management for future operations, including plans and objectives relating to the
products and future economic performance of the Company. In addition, all
statements other that statements of historical facts that address activities,
events, or developments the Company expects, believes, or anticipates will or
may occur in the future, and other such matters, are forward-looking statements.
The forward-looking statements included herein are based on current
expectations that involve a number of risks and uncertainties. These
forward-looking statements are based on assumptions that the Company will retain
key management personnel, the Company will be successful in the development of
the BACcelr8r, the Company will be able to protect its intellectual property,
the Company's ability to respond to technological change, that the Company will
accurately anticipate market demand for the Company's products and that there
will be no material adverse change in the Company's operations or business.
Assumptions relating to the foregoing involve judgments with respect to, among
other things, future economic, competitive and market conditions and future
business decisions, all of which are difficult or impossible to predict
accurately and many of which are beyond the control of the Company. Although the
Company believes that the assumptions underlying the forward-looking statements
are reasonable, any of the assumptions could prove inaccurate and, therefore,
there can be no assurance that the results contemplated in forward-looking
statements will be realized. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.
The following discussion should be read in conjunction with the Company's
unaudited financial statements and related notes included elsewhere herein. The
Company's future operating results may be affected by various trends and factors
which are beyond the Company's control. These include, among other factors,
general public perception of issues and solutions, and other uncertain business
conditions that may affect the Company's business. The Company cautions the
reader that a number of important factors discussed herein, and in other
reports, filed with the Securities and Exchange Commission including its 10-KSB
for the year ended July 31, 2004, could affect the Company's actual results and
cause actual results to differ materially from those discussed in
forward-looking statements.
Overview
Prior to January 2001, Accelr8 Technology Corporation ("Accelr8" or the
"Company") was primarily a provider of software tools and consulting services.
11
Accelr8 Technology Corporation
On January 18, 2001, Accelr8 purchased the OpTest technology assets from
DDx and commenced investment in development and optimization of OpTest's surface
chemistry (OptiChem) and quantitation instrument (QuanDx(TM)). The Company's
proprietary surface chemistry and its quantitation instruments support real-time
assessment of medical diagnostics, food-borne pathogens, water-borne pathogens,
and bio-warfare assessments. The OptiChem activated surface has the ability to
shed sticky biomolecules that interfere with bio-analytical assays such as
microarrays and immunoassays. Management believes that this property
substantially improves analytical performance by enabling higher sensitivity,
greater reproducibility, and higher throughput by virtue of simplified
application methods.
In July 2003, the Company introduced its OptiPlate(TM) products, which are
96- and 384-well glass bottom microtiter plates for multiplexed microarraying.
These products allow the customers to print a small microarray (as many as 2,000
spots) in each well. As with OptiChem slides, the products support both DNA and
protein microarraying. The glass and chemical coatings are identical to those
used in OptiChem slides. Management believes that this high throughput mode is
essential in drug discovery and diagnostics where a lab must validate an assay
over a large number of individual samples. The Company knows of only one other
US company (Fisher Scientific) and at least one European company that is selling
a plate for multiplexed microarraying.
On November 24, 2004, we entered into an exclusive global manufacturing and
distribution licensing agreement (the "License Agreement) with Schott Nexterion
(Schott Jenaer Glas GmbH, Jena, Germany "SCHOTT") and a supply agreement (the
"Supply Agreement") for microarray slides using Accelr8's OptiChem(R) surface
chemistry. (See Note 4 to the Financial Statements.) On June 2, 2005, the
Company signed a new supply agreement (the "New Supply Agreement") with SCHOTT
for a new product, a Streptavidin coated microarraying slide (the "Slide HS").
(See Note 5 to the Financial Statements.)
In January 2004, management commenced development of the BACcelr8r, a rapid
bacterial identification and antibiotic resistance detection platform.
The BACcelr8r embodies all three of Accelr8's wholly owned core technologies:
OptiChem surface chemistry, QuanDx optical detection, and YoDx(TM) accelerated
assay processing. We believe that the same integrated technology combination
will provide a platform for molecular analysis, as used in genomics and
proteomics, and molecular diagnostics. We expect the benefits of BACcelr8r to be
very high sensitivity, rapid results, high reproducibility, and relatively low
cost per test and expect the BACelr8r will be initially used in the ICU
(intensive care units) of hospitals for the diagnosis and treatment assessment
of VAP (ventilator associated pneumonia).
In fiscal 2006 we intend to complete technical studies on materials and
processes to be used in the BACcelr8r system. We believe that the BACcelr8r will
significantly speed up bacterial testing and improve treatment outcomes. By
developing and selling the system we intend to generate revenues and prove the
value of our technology to large diagnostic companies. We believe that the most
significant achievement of the BACcelr8r may be its ability to provide the
12
Accelr8 Technology Corporation
physician with rapid antibiotic susceptibility tests results. We believe that
this information should increase the number of lives saved by eliminating the
often-ineffective use of "empiric therapy" (when specific bacteria have not been
identified, the doctor prescribes a cocktail of drugs, hoping that the
combination will kill the bacteria).
Furthermore, we believe that dramatic compression of time that the
BACcelr8r will provide compared to standard culturing practices, will give
doctors an increased chance of getting patients out of the Intensive Care Unit
days ahead of present norms (typically 6 to 10 extra days for pneumonia). We
believe that this reduction in ICU costs, estimated at $3-4,000 per day, should
also significantly reduce un-reimbursed hospital costs, improving the bottom
line of an operating hospital budget. During the most recent quarter ending
October 31, 2005, we devoted substantially all of our internal resources to
testing of an 8-channel cassette that is the test bed for Version 0.1 of the
BACcelr8r prototype. Our in-house scientists directed our various outside
engineering consultants in further development of instrument software, image
analysis software for conversion of digitized photos of bacteria to analytical
data. We also began cassette design for Version 0.4 BACcelr8r. In addition we
have commenced custom antibody development for rapid bacterial identification
and count.
Current design concepts anticipate a 64-channel cassette. The Version 0.4
prototype will enable simultaneous testing of four separate 64-channel
cassettes, each cassette analyzing a different sample. Version 0.4 contemplates
increased throughput for bacterial identification and count while offering
antibiotic resistance testing. The Company foresees the development of Version
0.4 to proceed through calendar year 2006.
Changes in Results of Operations: three months ended October 31, 2005 compared
to three months ended October 31, 2004.
OptiChem revenues during the three month period ended October 31, 2005 were
$44,388 as compared to $21,724 during the three month period ended October 31,
2004, an increase of $22,664 or 104.3%. This increase was primarily the result
of sales of OptiChem slides under the HS Supply Agreement with SCHOTT. OptiChem
revenues for the three months ended October 31, 2005 were 51.4% of total
revenues and 100% of total revenues for the three months ended October 31, 2004.
During the three months ended October 31, 2005, sales of OptiChem slides to
the Company's largest customer were $37,713, representing 43.7% of the Company's
total revenues. During the three months ended October 31, 2004, sales to the
Company's largest customer were $18,774 representing 86.4% of total revenues.
The largest customer during the three month periods ending October 31, 2005 and
2004 was SCHOTT. The loss of this customer would have a material adverse effect
on the Company's financial performance if the Company was unable to replace the
revenue received from this customer.
13
Accelr8 Technology Corporation
Consulting fees during the three-month period ended October 31, 2005 were
$15,000 as compared to $0 during the three-month period ended October 31, 2004.
These technical consulting fees were the result of the completion of training
provided to SCHOTT for the manufacture of Slide H.
During the three month period ended October 31, 2005, development fees were
$27,000 as compared to $0 during the three month period ended October 31, 2004.
The development fees were the result of the Agreement with Promega to develop
new surface chemistry technology (See Note 5 to the Financial Statements.)
Cost of sales for the three months ended October 31, 2005 was $13,892,
which represented 31.3% of OptiChem revenue compared to $10,530 during the three
months ended October 31, 2004, which represented 48.5% of OptiChem revenue. The
decrease in the cost of sales expressed as a percentage of OptiChem revenue was
the result of efficiencies in production as new methods were developed which
reduced manpower costs. Further, reduced costs of substrates and chemicals used
in the formulation of OptiChem also contributed to this decrease.
Research and development expenses for the three months ended October 31,
2005 were $572,911 as compared to $203,149 during the three months ended October
31, 2004, an increase of $369,762 or 182%. This increase was primarily due to
increased scientific staff and the consulting fees related to the development of
BACcelr8r.
General and administrative expenses for the three months ended October 31,
2005 were $212,251 as compared to $261,056 during the three months ended October
31, 2004, a decrease of $48,805 or 18.6%. This decrease was primarily due to
decreases in consulting fees, corporate and shareholder expenses and corporate
insurance.
The increase in amortization was negligible for the three months ended
October 31, 2005 as compared to the three month period ended October 31, 2004.
Marketing and sales expenses for the three months ended October 31, 2005
were $28,479 as compared to $10,749 during the three months ended October 31,
2004, an increase of $17,730 or 165.0 %. This was primarily due to a contract
with an outside firm for a market research report, offset in part by a reduction
in salary expense due to outsourcing of our network support.
Depreciation for the three months ended October 31, 2005 was $19,031 as
compared to $15,405 during the three months ended October 31, 2004, an increase
of $3,626 or 23.5%. This increase resulted from depreciation of additional
laboratory equipment placed into service.
As a result of these factors, loss from operations for the three months
ended October 31, 2005 was $819,347 as compared to a loss of $537,863 during the
three months ended October 31, 2004, an increased loss of $281,484 or 52.3%.
14
Accelr8 Technology Corporation
Interest income during the three months ended October 31, 2005 was $47,372
as compared to $28,766 during the three months ended October 31, 2004, an
increase of $18,606 or 64.7%. Interest income increased as a result of increased
interest rates on the amounts of cash held by the Company.
An unrealized holding loss on marketable securities held in the deferred
compensation trust for the three months ended October 31, 2005 was $8,062 as
compared to $703 for the three months ended October 31, 2004, a difference of
$7,359. The change was the result of market fluctuations in the price of
securities held in the deferred compensation trust.
As a result of these factors, net loss for the three months ended October
31, 2005 was $772,038 as compared to $509,803 during the three months ended
October 31, 2004, an increased loss of $262,235 or 51.4%.
Capital Resources and Liquidity
At October 31, 2005, as compared to July 31, 2005, cash and cash
equivalents, decreased by $642,205 from $5,564,259 to $4,922,054, or
approximately 11.5% and the Company's working capital decreased by 13.0% from
$5,633,524 to $4,877,687. During the same period, shareholders' equity decreased
from $9,668,340 to $8,913,852 or approximately 7. 7% as a result of a net loss
of $772,038 offset by the receipt of $15,000 for the exercise of 10,000 stock
options.
The net cash used in operating activities was $825,299, in the three months
ended October 31, 2005 compared to cash used in operating activities of $298,072
in the three months ended October 31, 2004. The principal elements that gave
rise to the increase of cash used were an increase in the net loss of $262,238,
a decrease in accrued liabilities of $218,744 and a net decrease in deferred
revenue in the amount of $23,000.
The Company has historically funded its operations generally through cash
flow generated from operations and equity financing. Management believes that
current cash balances plus cash flow from operations will be sufficient to fund
our capital and liquidity needs for at least the next twenty-four months.
Item 3. Controls and Procedures
-------------------------------
An evaluation was conducted under the supervision and with the participation of
the Company's management, including Thomas V. Geimer, the Company's Chief
Executive Officer ("CEO") and Chief Financial Officer ("CFO"), of the
effectiveness of the design and operation of the Company's disclosure controls
and procedures as of October 31, 2005. Based on that evaluation, Mr. Geimer
concluded that the Company's disclosure controls and procedures were effective
as of such date to ensure that information required to be disclosed in the
reports that it files or submits under the Securities Exchange Act of 1934, as
amended, is recorded, processed, summarized and reported within the time periods
specified in SEC rules and forms. Such officers also confirm that there was no
change in the Company's internal control over financial reporting during the
quarter ended October 31, 2005.
15
Accelr8 Technology Corporation
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
-------------------------
Not Applicable.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
-------------------------------------------------------------------
Not applicable.
Item 3. Defaults upon Senior Securities
---------------------------------------
Not applicable.
Item 4. Submission of Matters to a Vote of Security Holders
-----------------------------------------------------------
Not applicable.
Item 5. Other Information
-------------------------
None
Item 6. Exhibits and Reports on Form 8-K
----------------------------------------
a) Exhibits:
1. Exhibit 31.1 Certification of Officer Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.
2. Exhibit 31.2 Certification of Officer Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.
3. Exhibit 32.1 Certification of Officer Pursuant to 18 U.S.C. 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act 0f 2002.
16
Accelr8 Technology Corporation
b) Reports on Form 8-K:
Form 8-K filed on September 28, 2005 disclosing Supply Agreement SCHOTT
Jenaer Glas GmbH
Form 8-K filed on October 182005 Disclosing Feasibility Testing Agreement
with Promega Corporation.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Dated: December 13, 2005 ACCELR8 TECHNOLOGY CORPORATION
By: /s/ Thomas V. Geimer
----------------------------------------
Thomas V. Geimer, Secretary, Chief
Executive Officer and Chief Financial
Officer
By: /s/ Joan D. Montgomery
----------------------------------------
Joan D. Montgomery, Principal Accounting
Officer
17